Uterine and Ovarian Cancer Trends Over the Past Two Decades: How Have Mortality Rates Changed Across Race and Ethnicity?
BACKGROUND AND PURPOSE:
Giaquinto et al. (Obstetrics & Gynecology, 2022) assessed mortality trends for uterine and ovarian cancer, including analysis by race and ethnicity
United States, between 1990 and 2019
Data on uterine and ovarian cancer death rates were obtained from SEER
Cancer death rates were age-standardized to the 2000 U.S. standard population and expressed per 100,000 person-years
Rates were stratified by mutually exclusive racial and ethnic categories: Asian or Pacific Islander, Black, Hispanic, or White
The average annual percent change was calculated using regression analysis
Mortality rate ratio (RR) comparing uterine and ovarian cancer and racial and ethnic subpopulations with White people were calculated
Uterine cancer death rates
Ovarian cancer death rates
Deaths from uterine cancer: 232,957 | Deaths from ovarian cancer: 419,085
Ovarian cancer mortality rates per 100,000 women decreased between 1990 and 2019
1990: 9.3 per 100,000 women
2019: 6.0 per 100,000 women
2010 to 2019 average annual percent change: −2.7% (95% CI, −3.5 to −2.0)
Uterine cancer mortality decreased from 1990 to 1997, but then increased by 2019
1990: 4.3 per 100,000 women
1997: 4.0 per 100,000 women
2019: 5.1 per 100,000 women
2010 to 2019 average annual percent change: 1.7% (95% CI 1.3 to 2.1%)
Ovarian cancer mortality decreased during the early 1990s to 2019
Early 1990s: 5.0 per 100,000 women
2019: 0.9 per 100,000 women
Uterine cancer mortality rate ratio for Black compared with White women increased between 1990 and 2019 (P<0.001)
1990 to 1994: RR 1.83 (95% CI, 1.77 to 1.89)
2015 to 2019: R 1.98 (95% CI, 1.93 to 2.02)
While in the 1990s mortality risk was 2 times higher for ovarian cancer than for uterine cancer, over the past 20 years this increased risk has mostly been eliminated by opposite mortality trends
Among Black women mortality disparities have widened
Black women face a twofold higher risk of uterine cancer mortality compared to White women, despite similar incidence
The authors state
…the gynecologic cancer landscape is changing rapidly, and the risk of death from uterine cancer is now similar to that for ovarian cancer among women overall and approximately 60% higher among Black women based on national mortality statistics
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan